Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(157 prodotti)
- Bcr-Abl(113 prodotti)
- EGFR(596 prodotti)
- FAK(72 prodotti)
- FLT(88 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(180 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(52 prodotti)
- VDA(2 prodotti)
- VEGFR(250 prodotti)
Mostrare 6 più sottocategorie
Trovati 2002 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Formula:C22H29N7O5Purezza:98%Colore e forma:SolidPeso molecolare:471.52CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Formula:C18H18ClNO4S3Purezza:98%Colore e forma:SolidPeso molecolare:443.99Cremastranone
CAS:Cremastranone: natural homoisoflavanone that hinders human retinal cell proliferation, migration, and tube creation.Formula:C18H18O7Colore e forma:SolidPeso molecolare:346.33BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purezza:97.26%Colore e forma:SolidPeso molecolare:516.6EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Colore e forma:SolidPeso molecolare:405.62Risvodetinib
CAS:Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.Formula:C33H34N8O2Colore e forma:SolidPeso molecolare:574.68Resigratinib
CAS:Resigratinib (KIN-3248) is an oral, irreversible pan-FGFR family protein inhibitor, covalently binds to and inhibits all four FGFR isoforms(FGFR1/2/3/4).Formula:C26H27F2N7O3Purezza:98.58%Colore e forma:SolidPeso molecolare:523.53HDAC-IN-50
CAS:HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.Formula:C31H41N7O4Colore e forma:SolidPeso molecolare:575.7BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Formula:C22H15BCl2N2O2Purezza:98%Colore e forma:SolidPeso molecolare:421.08TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Formula:C26H17F4N5O4Colore e forma:SolidPeso molecolare:539.44MET kinase-IN-3
CAS:MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.Formula:C25H16ClF2N5O2Colore e forma:SolidPeso molecolare:491.88BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formula:C22H25BrN4O2Purezza:99.02%Colore e forma:SolidPeso molecolare:457.3610Z-Hymenialdisine
CAS:Pan kinase inhibitorFormula:C11H10BrN5O2Purezza:98%Colore e forma:Light Yellow SolidPeso molecolare:324.13FGFR-IN-2
CAS:FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).Formula:C25H30N6O2Colore e forma:SolidPeso molecolare:446.54HPK1-IN-2 dihydrochloride
CAS:HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].Formula:C19H22Cl2N6OSColore e forma:SolidPeso molecolare:453.39CP-547632 TFA
CAS:CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.Formula:C22H25BrF5N5O5SPurezza:98%Colore e forma:SolidPeso molecolare:646.43VEGFR-2-IN-9
CAS:VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.Formula:C23H25N3O3Purezza:97.19%Colore e forma:SolidPeso molecolare:391.46DW10075
CAS:DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.Formula:C29H23N5O3Colore e forma:SolidPeso molecolare:489.52FGFR-IN-4
CAS:FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.Formula:C24H21N7O2Colore e forma:SolidPeso molecolare:439.47BTK inhibitor 13
CAS:BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Formula:C29H26FN5O3Purezza:98%Colore e forma:SolidPeso molecolare:511.55ALK-IN-6
CAS:ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).Formula:C26H29ClD3N5O3SPurezza:98%Colore e forma:SolidPeso molecolare:533.1Pivanex
CAS:Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.Formula:C10H18O4Purezza:≥98%Colore e forma:SolidPeso molecolare:202.25EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formula:C28H33BrN7O2PColore e forma:SolidPeso molecolare:610.49DosatiLink-2
CAS:DosatiLink-2 is an inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Formula:C65H85Cl2F2N13O15SColore e forma:SolidPeso molecolare:1429.42CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Formula:C26H29N7O2Purezza:99.63%Colore e forma:SolidPeso molecolare:471.55EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Colore e forma:SolidPeso molecolare:538.64BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formula:C26H22ClN5O3Colore e forma:SolidPeso molecolare:487.94FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Formula:C25H22N4O5Colore e forma:SolidPeso molecolare:458.47PF-06250112
CAS:PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.Formula:C22H20F2N6O2Purezza:98%Colore e forma:SolidPeso molecolare:438.43KB SRC 4
CAS:KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4Formula:C32H23ClN8Purezza:98.83% - 99.34%Colore e forma:SolidPeso molecolare:555.03MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Formula:C46H54ClFN8O8Colore e forma:SolidPeso molecolare:901.42JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFormula:C22H24N6O3Purezza:98%Colore e forma:SolidPeso molecolare:420.46EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColore e forma:SolidPeso molecolare:729.57SD 1008
CAS:SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.Formula:C18H19NO5Purezza:98%Colore e forma:SolidPeso molecolare:329.35SNIPER(TACC3)-11
CAS:SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.Formula:C51H66N10O7S2Colore e forma:SolidPeso molecolare:995.26UNC4203
CAS:UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.Formula:C30H44N6OColore e forma:SolidPeso molecolare:504.71HIF-2α-IN-1
CAS:HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.Formula:C16H8F5NO4SPurezza:97.99%Colore e forma:SolidPeso molecolare:405.315-deoxy-Δ12,14-Prostaglandin D2
CAS:15-deoxy-Δ12,14-Prostaglandin D2 (15-deoxy-Δ12,14-PGD2) is a PGD2 metabolite functioning as an agonist for the PGD2 receptor 2 (DP2), with a binding affinity (Ki) of 50 nM for the mouse DP2 receptor expressed in HEK293 cell membranes. It activates eosinophils with an EC50 of 8 nM and enhances the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), initiating PPARγ-mediated transcription at 5 µM concentration. Furthermore, it exhibits cytotoxicity towards L1210 murine leukemia cells with an IC50 of 0.3 µg/ml and displays weaker inhibition of ADP-induced platelet aggregation than PGD2, with an IC50 of 320 ng/ml.Formula:C20H30O4Colore e forma:SolidPeso molecolare:334.456JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Formula:C20H25N5O2Colore e forma:SolidPeso molecolare:367.44Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Formula:C30H52N2O8Colore e forma:SolidPeso molecolare:568.74Atiprimod dihydrochloride
CAS:JAK2 inhibitor; IC50=397 nM; hampers STAT3/5 phosphorylation; curbs growth and triggers apoptosis in JAK2V617F+ cells.Formula:C22H46Cl2N2Colore e forma:SolidPeso molecolare:409.52SG3-179
CAS:SG3-179 is a BET inhibitor.Formula:C28H35ClFN7O3SColore e forma:SolidPeso molecolare:604.14N-desmethyl Regorafenib N-oxide
CAS:N-Desmethyl Regorafenib N-oxide, an active metabolite of the multi-kinase inhibitor regorafenib, originates through the action of the cytochrome P450 (CYP) isoform CYP3A4. This compound demonstrates efficacy in vitro by inhibiting key enzymes such as VEGFR2, Tie2, c-Kit, and B-RAF, and it exhibits tumor growth inhibition in HT-29 and MDA-MB-231 mouse xenograft models at a dosage of 1 mg/kg.Formula:C20H13ClF4N4O4Colore e forma:SolidPeso molecolare:484.79Itacnosertib (hydrocholide)
CAS:Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].Formula:C26H29ClN8OColore e forma:SolidPeso molecolare:505.01Tyrphostin AG1433
CAS:Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).Formula:C16H14N2O2Purezza:98.47%Colore e forma:SolidPeso molecolare:266.29Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Formula:C20H17N9Purezza:98%Colore e forma:SolidPeso molecolare:383.41YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formula:C30H30N4O3Purezza:98%Colore e forma:SolidPeso molecolare:494.58JAK-IN-17
"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."Formula:C33H38F2N6O8Colore e forma:SolidPeso molecolare:684.69TL02-59
CAS:TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.Formula:C32H34F3N5O4Purezza:98.77%Colore e forma:SolidPeso molecolare:609.64FGFR-IN-8
CAS:FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.Formula:C27H31Cl2N9O2Colore e forma:SolidPeso molecolare:584.5PI3K/VEGFR2-IN-1
CAS:PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.Formula:C17H14ClN3OSPurezza:98%Colore e forma:SolidPeso molecolare:343.83BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formula:C26H23N7O2Colore e forma:SolidPeso molecolare:465.51BCR-ABL-IN-4
CAS:BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).Formula:C27H24ClF2N5O4Colore e forma:SolidPeso molecolare:555.96PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purezza:98%Colore e forma:SolidPeso molecolare:431.88BPR1J-340
CAS:BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.Formula:C29H34N8O3Colore e forma:SolidPeso molecolare:542.63Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Formula:C25H26ClFN4O4Purezza:99.7%Colore e forma:SolidPeso molecolare:500.95PonatiLink-1-24
CAS:Ponatinib, also known as PonatiLink-1-24, is a selective inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Formula:C101H144ClF5N12O29Colore e forma:SolidPeso molecolare:2120.73OTS447
CAS:OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .Formula:C27H32ClN3O2Purezza:98.78%Colore e forma:SolidPeso molecolare:466.02Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purezza:98%Colore e forma:SolidPeso molecolare:602.521JNJ-17029259
CAS:JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).Formula:C26H30N6OPurezza:98%Colore e forma:SolidPeso molecolare:442.56DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Formula:C60H77Cl2N13O3SColore e forma:SoildPeso molecolare:1131.31JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purezza:98%Colore e forma:SolidPeso molecolare:380.44FLT3-IN-14
CAS:FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.Formula:C25H24N6O2SColore e forma:SolidPeso molecolare:472.56JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formula:C33H41ClN8O2Purezza:98.75%Colore e forma:SolidPeso molecolare:617.18BMX-IN-1
CAS:BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFormula:C29H24N4O4SPurezza:98.38%Colore e forma:SolidPeso molecolare:524.59PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Formula:C22H21ClN6O2Colore e forma:SolidPeso molecolare:436.89Roslin 2 bromide
CAS:Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.Formula:C13H19BrN4Purezza:99.34%Colore e forma:SolidPeso molecolare:311.22JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formula:C22H23BrFN5O2Purezza:98%Colore e forma:SolidPeso molecolare:488.35Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Formula:C30H37N7O2Colore e forma:SolidPeso molecolare:527.66Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFormula:C26H21F2N5O3Purezza:99.41%Colore e forma:SolidPeso molecolare:489.47TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Formula:C26H27Cl2N5O2Purezza:98%Colore e forma:SolidPeso molecolare:512.43ALK/EGFR-IN-1
CAS:ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.Formula:C27H34ClN7O3SPurezza:98%Colore e forma:SolidPeso molecolare:572.12Famitinib malate
CAS:Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.Formula:C27H33FN4O7Colore e forma:SolidPeso molecolare:544.57SIM010603
CAS:SIM010603, an oral RTK inhibitor, targets Kit, VEGFR-2, PDGFR-β, RET, FLT3 (IC50: 5.0-68.1 nmol/l), inhibits cell proliferation and angiogenesis.Formula:C22H25FN4O2Colore e forma:SolidPeso molecolare:396.46PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Formula:C23H18ClF2N3O2SPurezza:98.84%Colore e forma:SolidPeso molecolare:473.92FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purezza:98%Colore e forma:SolidPeso molecolare:442.523BPIQ-I
CAS:BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.Formula:C16H12BrN5Colore e forma:SolidPeso molecolare:354.2TIE-2/VEGFR-2 kinase-IN-5
CAS:TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.Formula:C21H13F6N5O2Purezza:99.79%Colore e forma:SolidPeso molecolare:481.35ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Formula:C27H34ClN7O3SColore e forma:SolidPeso molecolare:572.12EGFR mutant-IN-1
EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.Formula:C34H39ClFN7O2Purezza:98%Colore e forma:SolidPeso molecolare:632.17HDAC/JAK/BRD4-IN-1
CAS:HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.Formula:C24H28N6O3Purezza:98%Colore e forma:SolidPeso molecolare:448.52BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formula:C20H22Cl2N6OColore e forma:SolidPeso molecolare:433.33ALK/EGFR-IN-3
CAS:ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-Formula:C27H34ClN7O3SColore e forma:SolidPeso molecolare:572.12VEGFR2-IN-3
CAS:VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].Formula:C26H28ClN5O4Purezza:98%Colore e forma:SolidPeso molecolare:509.98BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purezza:99.98%Colore e forma:SolidPeso molecolare:567.01Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFormula:C22H20N6O3Colore e forma:SolidPeso molecolare:416.43GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formula:C24H26N2O2Colore e forma:SolidPeso molecolare:374.48JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Formula:C19H17N5O4Purezza:98%Colore e forma:SolidPeso molecolare:379.37TIE-2/VEGFR-2 kinase-IN-3
CAS:TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 valuesFormula:C23H17F4N5O3SColore e forma:SolidPeso molecolare:519.47DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFormula:C28H27F2N7O3Purezza:98%Colore e forma:SolidPeso molecolare:547.56UNC5293
CAS:UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.Formula:C30H42N6O2Colore e forma:SolidPeso molecolare:518.69T338C Src-IN-1
CAS:T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).Formula:C17H20N6O2SPurezza:98%Colore e forma:SolidPeso molecolare:372.44Brolucizumab
CAS:Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.Purezza:95%Colore e forma:LiquidVEGFR-2-IN-37
CAS:VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.Formula:C18H16N2O2SPurezza:98%Colore e forma:SolidPeso molecolare:324.4EGFR-IN-29
CAS:EGFR-IN-29 is a potent EGFR inhibitor.Formula:C36H46BrN8O2PColore e forma:SolidPeso molecolare:733.68Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purezza:99.85%Colore e forma:SolidPeso molecolare:355.39BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Formula:C37H42N8O4Colore e forma:SolidPeso molecolare:662.78(Rac)-PF-06250112
CAS:(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Formula:C22H20F2N6O2Purezza:98%Colore e forma:SolidPeso molecolare:438.43GW-6604
CAS:GW-6604 is an ALK5 inhibitor and shows clear antifibrotic effects resulting in liver function improvement.Formula:C19H14N4Purezza:99.6%Colore e forma:SolidPeso molecolare:298.34EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Formula:C28H32F2N6O5Purezza:99.08% - 99.38%Colore e forma:SolidPeso molecolare:570.59FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Formula:C23H25N7O2Colore e forma:SolidPeso molecolare:431.49Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Colore e forma:SolidPeso molecolare:761.91EVT801
CAS:EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.Formula:C19H21N5O3Purezza:97.4%Colore e forma:SolidPeso molecolare:367.4ALK/ROS1-IN-1
CAS:ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).Formula:C30H35F3N6O3Purezza:98%Colore e forma:SolidPeso molecolare:584.63JAK-IN-4
CAS:JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.Formula:C18H21N4Na2O6PPurezza:98%Colore e forma:SolidPeso molecolare:466.341Infigratinib-Boc
CAS:Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].Formula:C29H35Cl2N7O5Colore e forma:SolidPeso molecolare:632.54Ruxolitinib sulfate
CAS:Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.Formula:C17H20N6O4SColore e forma:SolidPeso molecolare:404.45Larixol
CAS:Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical forFormula:C20H34O2Purezza:98%Colore e forma:SolidPeso molecolare:306.48EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97Lifirafenib
CAS:Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinantFormula:C25H17F3N4O3Purezza:97.99% - 98%Colore e forma:SolidPeso molecolare:478.42TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Formula:C17H11ClF2N4O2Colore e forma:SolidPeso molecolare:376.74Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Formula:C24H28N6O3SPurezza:99.21% - >99.99%Colore e forma:SolidPeso molecolare:480.58EGFR kinase inhibitor 1
CAS:Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.Formula:C30H31N7O2Colore e forma:SolidPeso molecolare:521.61(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formula:C16H14N2O2Colore e forma:SolidPeso molecolare:266.29CT-721
CAS:CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.Formula:C30H29ClN6OPurezza:98%Colore e forma:SolidPeso molecolare:525.04ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Formula:C23H22ClFN6OPurezza:99.71%Colore e forma:SolidPeso molecolare:452.91BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purezza:99.89%Colore e forma:SolidPeso molecolare:502.56IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Formula:C25H20N6OPurezza:99.79%Colore e forma:SolidPeso molecolare:420.47TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purezza:98.66%Colore e forma:SolidPeso molecolare:351.36KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Formula:C26H30FN7OPurezza:98.49% - >99.99%Colore e forma:SolidPeso molecolare:475.56EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purezza:99.16%Colore e forma:SolidPeso molecolare:551.04EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purezza:98.64%Colore e forma:SolidPeso molecolare:499.61Ifebemtinib
CAS:Ifebemtinib (BI-853520) is an adhesion plaque kinase inhibitor with anti-tumour activity for the study of breast cancer.Formula:C28H28F4N6O4Purezza:98.84% - 99.85%Colore e forma:SolidPeso molecolare:588.55CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Formula:C26H22F2N6O4SPurezza:98.87%Colore e forma:SolidPeso molecolare:552.55Zongertinib
CAS:Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (Formula:C29H29N9O2Purezza:98.24%Colore e forma:SolidPeso molecolare:535.6Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purezza:99.81%Colore e forma:SolidPeso molecolare:484.93Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Formula:C34H32ClFN8O4Purezza:98.35%Colore e forma:SolidPeso molecolare:671.12HM43239
CAS:HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.Formula:C29H33ClN6Purezza:99.7%Colore e forma:SolidPeso molecolare:501.07VEGFR-2-IN-18
VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.Formula:C20H13ClN4O2Colore e forma:SolidPeso molecolare:376.8FAK inhibitor 6
CAS:Compound 26F: potent enzyme inhibitor (IC50=28.2nM), low cytotoxicity (IC50=3.32μM), induces dose-dependent apoptosis in MDA-MB-231, blocks G0/G1 phase.Formula:C25H24FN5O2SColore e forma:SolidPeso molecolare:477.55FGFR4-IN-6
FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.Formula:C31H33N7O4Colore e forma:SolidPeso molecolare:567.64EGFR/HER2-IN-6
EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.Formula:C18H21N5O3SColore e forma:SolidPeso molecolare:387.46Tyk2-IN-3
CAS:Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formula:C25H24N6O3S2Purezza:98%Colore e forma:SolidPeso molecolare:520.63BTK-IN-7
BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.Formula:C30H32N6O4Colore e forma:SolidPeso molecolare:540.61Multi-kinase inhibitor 4
CAS:Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.Formula:C25H24N6O2Colore e forma:SolidPeso molecolare:440.50(-)-Cevimeline hydrochloride hemihydrate
(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.Formula:C10H19ClNO1·5SPurezza:98%Colore e forma:SolidPeso molecolare:244.78JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formula:C31H31F3N8O4Colore e forma:SolidPeso molecolare:639.64YSY01A
CAS:YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.Formula:C29H38BN5O5Colore e forma:SolidPeso molecolare:547.45EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Colore e forma:SolidPeso molecolare:546.64ALK/PI3K/AKT-IN-1
CAS:ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.Formula:C25H20FN5O2SColore e forma:SolidPeso molecolare:473.522FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Formula:C28H31ClN8O3Colore e forma:SolidPeso molecolare:563.05HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Colore e forma:SolidPeso molecolare:504.58Tofacitinib Prodrug-1
Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.Formula:C36H39ClN10O7Colore e forma:SolidPeso molecolare:759.21SILA-123
CAS:<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Formula:C24H25N5O2Colore e forma:SolidPeso molecolare:415.49EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Colore e forma:SolidPeso molecolare:490.98Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Formula:C26H26N6O2Colore e forma:SolidPeso molecolare:454.52CLM3
CAS:<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Formula:C21H21N5Colore e forma:SolidPeso molecolare:343.43FAK-IN-26
CAS:<p>FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.</p>Formula:C20H19BrFN5O2Colore e forma:SolidPeso molecolare:460.30ERBB agonist-1
CAS:ERBB agonist-1 (Compound EF-1) is an ERBB4 agonist that activates the ERBB4 signaling pathway by inducing ERBB4 receptor dimerization, with an EC50 of 10.5 μM. It promotes phosphorylation of Akt and ERK1/2, reduces collagen expression in cardiac fibroblasts, and inhibits H2O2-induced cardiomyocyte death and Ang II-induced cardiac hypertrophy. Furthermore, ERBB agonist-1 can prevent myocardial fibrosis and demonstrates cardioprotective effects in mouse models.Formula:C24H25N3O2SColore e forma:SolidPeso molecolare:419.539Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Colore e forma:SolidPeso molecolare:599.08SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Formula:C27H26ClF4N5OColore e forma:SolidPeso molecolare:547.98LT-850-166
LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.Formula:C30H29Cl2N7OColore e forma:SolidPeso molecolare:574.5CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Formula:C32H30N6O3Colore e forma:SolidPeso molecolare:546.619VEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Formula:C29H22BrN5SColore e forma:SolidPeso molecolare:552.49BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formula:C18H15N3O2Colore e forma:SolidPeso molecolare:305.331I194496
CAS:<p>I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.</p>Formula:C28H23F2N5O5SColore e forma:SolidPeso molecolare:579.58HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColore e forma:SolidPeso molecolare:423.23HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Colore e forma:SolidPeso molecolare:549.53Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formula:C19H20FN5OSColore e forma:SolidPeso molecolare:385.458ALKBH5-IN-3
CAS:ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Formula:C11H7F3N2O3Purezza:98.32%Colore e forma:SolidPeso molecolare:272.18VEGFR-2-IN-25
CAS:VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).Formula:C24H22N6O2Colore e forma:SolidPeso molecolare:426.47VEGFR-2-IN-5 hydrochloride
VEGFR-2-IN-5 hydrochloride is an effective VEGFR2 inhibitor.Formula:C19H25ClN8Colore e forma:SolidPeso molecolare:400.91EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColore e forma:SolidPeso molecolare:328.39Squalamine
CAS:Squalamine is an aminosterol compound, with potent broad spectrum antiviral activity.Formula:C34H65N3O5SPurezza:98%Colore e forma:SolidPeso molecolare:627.96DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColore e forma:SolidPeso molecolare:400.362FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Formula:C28H30N4O2Colore e forma:SolidPeso molecolare:454.56JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColore e forma:SolidPeso molecolare:556.65FLT3/ITD-IN-1
FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.Formula:C19H22N6O2Colore e forma:SolidPeso molecolare:366.42EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Formula:C28H23N7OColore e forma:SolidPeso molecolare:473.53VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Formula:C22H24N6O3SColore e forma:SolidPeso molecolare:452.53FLT3-IN-13
<p>FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.</p>Formula:C20H14N4O2Colore e forma:SolidPeso molecolare:342.35EGFR-IN-47
EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.Formula:C29H35N7Colore e forma:SolidPeso molecolare:481.64JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColore e forma:SolidPeso molecolare:440.93Lucitanib dihydrochloride
CAS:Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.Formula:C26H27Cl2N3O4Colore e forma:SolidPeso molecolare:516.42BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Colore e forma:SolidPeso molecolare:587.45EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96FAK-IN-6
FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.Formula:C25H31ClN5O6PSColore e forma:SolidPeso molecolare:596.04ALK-IN-31
CAS:ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Formula:C30H33N5O2SColore e forma:SolidPeso molecolare:527.68MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Formula:C22H14Cl2FN5O2SColore e forma:SolidPeso molecolare:502.348FGFR-IN-5
CAS:FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.Formula:C25H22N6O3Colore e forma:SolidPeso molecolare:454.48RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Formula:C29H37Cl2N7O4Colore e forma:SolidPeso molecolare:618.55EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Formula:C20H16N4Colore e forma:SolidPeso molecolare:312.368Lomonitinib
CAS:<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Formula:C27H24N4O2Colore e forma:SolidPeso molecolare:436.505MM-589
CAS:<p>MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.</p>Formula:C28H44N8O5Purezza:98%Colore e forma:SolidPeso molecolare:572.70VEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Formula:C20H21N3O2Colore e forma:SolidPeso molecolare:335.4EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Colore e forma:SolidPeso molecolare:476.951EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Colore e forma:SolidPeso molecolare:481.97Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formula:C31H36N8O3Colore e forma:SolidPeso molecolare:568.669CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Formula:C18H14N4Colore e forma:SolidPeso molecolare:286.331Ki11502
CAS:Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.Formula:C26H23N3O4SPeso molecolare:473.54LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Colore e forma:SolidPeso molecolare:413.854Lazertinib mesylate
CAS:<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Formula:C31H38N8O6SPeso molecolare:650.75PNU-145156E
CAS:PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.Formula:C45H40N10O17S4Colore e forma:SolidPeso molecolare:1121.12Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColore e forma:SolidPeso molecolare:426.42JAK1/TYK2-IN-4
CAS:JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formula:C17H23N7OColore e forma:SolidPeso molecolare:341.41EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Colore e forma:SolidPeso molecolare:284.27JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formula:C23H22Cl2N4OColore e forma:SolidPeso molecolare:441.35Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formula:C22H21N9O2Colore e forma:SolidPeso molecolare:443.46Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColore e forma:SolidPeso molecolare:429.47
